Carbon-Ion Radiotherapy Using Metal Artifact Reduction Computed Tomography in a Patient with Prostate Cancer with Bilateral Hip Prostheses: A Case Report

Autor: Yosuke Takakusagi, Yoshiki Takayama, Yohsuke Kusano, Hiroaki Koge, Kio Kano, Satoshi Shima, Keisuke Tsuchida, Nobutaka Mizoguchi, Daisaku Yoshida, Tadashi Kamada, Shin Miyakawa, Koh Imura, Hiroyuki Katoh
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: Case Reports in Oncology, Vol 15, Iss 3, Pp 894-901 (2022)
Druh dokumentu: article
ISSN: 1662-6575
DOI: 10.1159/000526932
Popis: Carbon-ion radiotherapy (CIRT) for prostate cancer is both safe and efficacious; beam range calculations use relative stopping power ratio, which is derived from computed tomography (CT) values. However, hip prostheses are made of high atomic number materials and show severe artifacts on CT images. Therefore, it is not possible to accurately calculate dose distribution for CIRT in patients with prostate cancer with hip prostheses. Here, we describe the management of a 77-year-old man with prostate cancer who had previously undergone bilateral hip replacement. CIRT, in combination with androgen deprivation therapy, was recommended as definitive treatment for prostate cancer. Planning CT, magnetic resonance (MRI), and CT images with metal artifact reduction (MAR) were acquired for CIRT planning. MRI and MAR images were superimposed on the planning CT to delineate target volume and organs at risk. The radiation treatment plan consisted of a total dose of 51.6 Gy (relative biological effect) to be delivered in 12 fractions over 3 weeks, and the patient was irradiated in the supine and prone positions with a vertical beam, on alternating days. CIRT was completed as scheduled. No adverse events were observed during treatment or at 3 months after treatment initiation. While we show that CIRT may be a treatment option for patients with prostate cancer with bilateral hip prostheses, further studies are needed to evaluate treatment efficacy and late toxicity and to determine how CIRT can be administered to patients with prostate cancer with bilateral hip prostheses.
Databáze: Directory of Open Access Journals
Nepřihlášeným uživatelům se plný text nezobrazuje